Your browser doesn't support javascript.
loading
Comparison of esophageal cancer survival after neoadjuvant chemoradiotherapy plus surgery versus definitive chemoradiotherapy: A systematic review and meta-analysis.
Ke, Junli; Xie, Yujie; Huang, Shenyang; Wang, Wei; Zhao, Zhengang; Lin, Wanli.
Afiliación
  • Ke J; Department of Thoracic Surgery, Gaozhou People's Hospital Affiliated to Guangdong Medical University, Maoming, China.
  • Xie Y; Department of Thoracic Surgery, Gaozhou People's Hospital Affiliated to Guangdong Medical University, Maoming, China.
  • Huang S; Department of Cardiothoracic Surgery, Guangdong Medical University, Zhanjiang, China.
  • Wang W; Graduate School of Guangdong Medical University, Zhanjiang, China.
  • Zhao Z; Department of Cardiothoracic Surgery, Guangdong Medical University, Zhanjiang, China.
  • Lin W; Department of Thoracic Surgery, Gaozhou People's Hospital Affiliated to Guangdong Medical University, Maoming, China. Electronic address: wanliLin2020@163.com.
Asian J Surg ; 47(9): 3827-3840, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38448293
ABSTRACT
Surgery after neoadjuvant chemoradiotherapy remains the gold standard for the treatment of resectable esophageal cancer (EC); however, chemoradiotherapy without surgery has been recommended in specific cases. The aim of this meta-analysis is to analyse the survival between surgeries after neoadjuvant chemoradiotherapy compared with definitive chemoradiotherapy in order to provide a theoretical basis for clinically individualised differential treatment. We conducted an initial search of MEDLINE (PubMed), the Cochrane Library, and Embase for English-only articles that compared treatment regimens and provided survival data. According to the final I2 value of the two survival indicators, the random effect model or fixed effect model was used to calculate the overall hazard ratio (HR) and 95% confidence intervals (CI). Cochrane's Q test was used to judge the heterogeneity of the studies, and a funnel plot was used to evaluate for publication bias. A sensitivity analysis was performed to verify the stability of the included studies. A total of 38 studies involving 29161 patients (neoadjuvant therapy 15401, definitive chemoradiotherapy 13760) were included in the analysis. The final pooled results (HR = 0.74, 95% CI 0.67-0.82) showed a statistically significant increase in overall survival with neoadjuvant chemoradiotherapy plus surgery compared with definitive chemoradiotherapy. Subgroup analyses were performed to determine the effects of heterogeneity, additional treatment regimens, study types, and geographic regions, as well as histologic differences, complications, and recurrence, on the overall results. For people with esophageal cancer that can be removed, neoadjuvant chemoradiotherapy combined with surgery improves survival compared to definitive chemoradiotherapy. However, more research is needed to confirm these results and help doctors make decisions about treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Esofagectomía / Terapia Neoadyuvante / Quimioradioterapia Límite: Humans Idioma: En Revista: Asian J Surg Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Esofagectomía / Terapia Neoadyuvante / Quimioradioterapia Límite: Humans Idioma: En Revista: Asian J Surg Año: 2024 Tipo del documento: Article País de afiliación: China